Key features and details | |
Cat. No. | MABL-1652 |
Name | Anti-ganglioside GD3 mAbs |
Clone No. | AFD- KM8871 |
From | Recombinant Antibody |
Isotype | Engineer antibody |
Application | neutralizing, Therapeutics development, ELISA |
Species Reactivity | Human |
Basic Information | |
Specificity | KM8871 recognizes ganglioside GD3, a prominent ganglioside of human melanoma, melanocytes and other cells of neuroectodermal origin. It cross-reacted weakly with GQ1b. |
Alternative Name | ganglioside; C68H121N3O29; (2S,4S,5R)-5-acetamido-6-[(1S,2R)-2- [(2S,4S,5R)-5-acetamido-2-carboxy-4-hydroxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]oxan-2-yl]oxy-1,3- dihydroxypropyl]-2-[(2S,3R,4S,5S,6R)-2-[(2R,3S,4R,6R)-6-[(E,2S,3R)-2-(hexadecanoylamino)-3- hydroxyoctadec-4-enoxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-3,5-dihydroxy-6- (hydroxymethyl)oxan-4-yl]oxy-4-hydroxyoxane-2-carboxylic acid; CHEBI:89636; d18:1/20:0 |
UniProt | |
Immunogen | This antibody was originally raised as a mouse IgG3 (clone KM641) which was turned into a mouse/human chimeric antibody KM871 and, finally, humanized by complementarity-determining region grafting and designated as KM8871 (Shitara et al., 1993; pmid: 8500110; Nakamura et al., 2001; pmid: 11499811). |
Application Notes | Ganglioside G3 is one of the major gangliosides expressed on most human cancers of neuroectodermal and epithelial origin and is a potential target for passive immunotherapy with monoclonal antibodies. This clone (KM8871) is recommended for the research and development of potential therapeuic agents for immunotherapy and target validation of ganglioside-based vaccine therapy (Nakamura et al., 2001; pmid: 11499811). The potent binding of the humanized antibody KM8871 to the ganglioside GD3 was confirmed by ELISA testing (Nakamura et al., 2001; pmid: 11499811). It was also demonstrated that KM8871 was able to induce CDC (complement-dependent cytotoxicity) and strong ADCC (antibody- dependent cellular cytotoxicity) against ganglioside GD3-expressing cancer cells (Nakamura et al., 2001; pmid: 11499811). Consequently, this humanized antibody can be further investigated as a potential therapetic candidate against various neuroectodermal and epithelial cancers, either alone or with active molecules conjugated to it. |
Antibody First Published | Nakamura et al. Construction of humanized anti-ganglioside monoclonal antibodies with potent immune effector functions Cancer Immunol Immunother. 2001 Jul;50(5):275-84. doi: 10.1007/pl00006689. PMID:11499811 |
Note on publication | Describes the generation and characterization of a humanized antibody KM8871 based on a previous mouse/human chimera. |
COA Information （For reference only, actual COA shall prevail） | |
Size | 100 μg Purified antibody. |
Concentration | 1 mg/ml. |
Purification | Protein A affinity purified |
Buffer | PBS with 0.02% Proclin 300. |
Concentration | 1 mg/ml. |
Storage Recommendation | Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at - 20⁰C. |
